Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.72 USD
Change Today +0.18 / 11.69%
Volume 16.5M
ENZN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Thomas F. Deuel M.D.

Former Director and Member of Compensation Committee, Enzon Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 32 board members in 2 different organizations across 4 different industries.

See Board Relationships
79$57,285

Background*

Dr. Thomas J. Deuel, Tom, serves as the Director of the Division of Molecular Oncology. Dr. Deuel also serves as the Director of Department of Molecular and Experimental Medicine and Director of the Vascular Biology Affinity Group at The Scripps Research Institute since February 2002. Dr. Deuel's areas of expertise include molecular biology, biochemistry, hematology, cardiology and oncology. He serves as the President of the Edward R. Mallinckrodt Foundation, St. Louis, ...

Read Full Background

Corporate Headquarters*

20 Kingsbridge Road
Piscataway, New Jersey 08854

United States

Phone: 732-980-4500
Fax: --

Board Members Memberships*

2007-2008
Former Director, Member of Audit Committee, Member of Compensation Committee and Member of Research & Development Oversight Committee
2010-2013
Former Director and Member of Compensation Committee

Education*

MD
Columbia University
BA
Princeton University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation$32,293
Total Calculated Compensation$57,285
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZN:US $1.72 USD +0.18

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Judith Greciet Ph.D., PharmacyChief Executive Officer, Director and Member of Corporate Development Committee
Onxeo SA
€424.3K
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
William John Edward Burt DPhilChief Executive Officer and Executive Director
Abzena plc
--
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZON PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.